UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number: 1-32001 APTOSE BIOSCIENCES INC. (Exact Name of Registrant as Specified in Its Charter) Canada (State or other jurisdiction of incorporation or ...

EXHIBIT 99.1 Aptose Reports Results for the First Quarter 2024 TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML Conference Call and Webcast at 5:00 pm ET Today SAN DIEGO and TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: ...

TUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by Extensive TUS and TUS+VEN Data from Completed Trials with R/R AML Conference Call and Webcast at 5:00 pm ET Today   SAN DIEGO and TORONTO, May 14, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company de ...

Aptose Biosciences (APTO) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Si ...

Aptose Biosciences Inc. (NASDAQ:APTO) Q4 2023 Earnings Conference Call March 26, 2024 5:00 PM ET Company Participants Susan Pietropaolo - Managing Director-Corporate Communications & Investor Relations William Rice - Chairman, President & Chief Executive Officer Fletcher Payne - Senior Vice President and Chief Financial Officer Rafael Bejar - Senior Vice President & Chief Medical Officer Conference Call Participants Soumit Roy - Jones Research Operator Good afternoon. My name is Jonathan and I will be your ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-32001 Aptose Biosciences Inc. (Exact name of Registrant as specified in its Charter) Canada 98-1136802 (State or other jurisdiction o ...

财务业绩 - Aptose Biosciences Inc.宣布2023年12月31日结束的三个月和全年财务业绩[1] - Aptose完成了公开发行，募集了约970万美元的总收入[3] - Aptose的现金、现金等价物和短期投资为9252万美元[8] - Aptose预计现金足以支持研发至2024年8月[9] 药物研发 - Tuspetinib在治疗AML患者中取得了良好的安全性和广泛活性[2] - Tuspetinib正在推进到三联疗法试验[4] - Tuspetinib正在进行三联疗法试验，包括venetoclax和低甲基化剂[6] - Luxeptinib G3配方已达到预期水平，为未来试验做好准备[5] 风险提示 - 公司提到了与风险和不确定性相关的事项，强调了实际结果可能与预期有较大差异[27] 联系方式 - 公司提供了联系方式，包括Susan Pietropaolo和Dan Ferry的联系信息[28]

Aptose Biosciences财务业绩发布 - Aptose Biosciences Inc.将于2024年3月26日发布截至2023年12月31日的第四季度和全年财务业绩，并提供企业更新[1] - 分析师可以通过预先注册的链接参与问答环节，并获得拨入号码和独特的PIN码，以便接入电话会议[2] Aptose Biosciences药物研发重点 - Aptose Biosciences致力于开发精准药物，重点关注血液学领域的未满足医疗需求，其药物管线包括针对血液肿瘤的口服激酶抑制剂[5]

公司财务业绩 - Aptose Biosciences Inc.将于2024年3月26日发布截至2023年12月31日的第四季度和全年财务业绩，并提供公司更新[1] 参与问答环节 - 分析师可以通过预先注册参与问答环节，获取拨入号码和独特的PIN码，以便接入电话会议[2] 药物管线 - Aptose Biosciences的小分子癌症治疗药物管线包括针对血液病的两种临床阶段口服激酶抑制剂，分别是tuspetinib (HM43239)和luxeptinib (CG-806)[5]

SAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) --  Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted agents to treat hematologic malignancies, today announced the closing of the previously announced public offering (the "Public Offering") of 5,649,122 common shares of the Company (the "Common Shares") and warrants at a combined offering price of US $1.71 per share. This includes 736,842 Com ...